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Abstract
Background: The Env glycoproteins of retroviruses play an important role in the initial steps of
infection involving the binding to cell surface receptors and entry by membrane fusion. The Env
glycoprotein also plays an important role in viral assembly at a late step of infection. Although the
Env glycoprotein interacts with viral matrix proteins and cellular proteins associated with lipid rafts,
its possible role during the early replication events remains unclear. Truncation of the cytoplasmic
tail (CT) of the Env glycoprotein is acquired by SIV in the course of adaptation to human cells, and
is known to be a determinant of SIV pathogenicity.
Results: We compared SIV viruses with full length or truncated (T) Env glycoproteins to analyze
possible differences in entry and post-entry events, and assembly of virions. We observed that early
steps in replication of SIV with full length or T Env were similar in dividing and non-dividing cells.
However, the proviral DNA of the pathogenic virus clone SIVmac239 with full length Env was
imported to the nucleus about 20-fold more efficiently than proviral DNA of SIVmac239T with T
Env, and 100-fold more efficiently than an SIVmac18T variant with a single mutation A239T in the
SU subunit and with a truncated cytoplasmic tail (CT). In contrast, proviral DNA of SIVmac18 with
a full length CT and with a single mutation A239T in the SU subunit was imported to the nucleus
about 50-fold more efficiently than SIVmac18T. SIV particles with full length Env were released
from rhesus monkey PBMC, whereas a restriction of release of virus particles was observed from
human 293T, CEMx174, HUT78 or macrophages. In contrast, SIV with T Envs were able to
overcome the inhibition of release in human HUT78, CEMx174, 293T or growth-arrested
CEMx174 cells and macrophages resulting in production of infectious particles. We found that the
long CT of the Env glycoprotein was required for association of Env with lipid rafts. An Env mutant
C787S which eliminated palmitoylation did not abolish Env incorporation into lipid rafts, but
prevented virus assembly.
Conclusion: The results indicate that the long cytoplasmic tail of the SIV Env glycoprotein may
govern post-entry replication events and plays a role in the assembly process.
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Background
The Env glycoproteins of retroviruses play an important
role in the initial steps of infection involving the binding
to cell surface receptors and entry by membrane fusion.
The Env glycoprotein also plays an important role in viral
assembly at a late step of infection. There is evidence for
intracellular interaction of Env with the matrix protein [1-
4], and the Env glycoprotein directly influences the site of
release of virus particles in polarized epithelial cells [5].
The cytoplasmic tail of the Env glycoprotein is required
for such interactions and has effects on Env incorporation
and infectivity [3,6]. In addition, removal of the cytoplas-
mic domain can increase the expression of Env on the sur-
face of infected cells, its incorporation into VLPs or
membrane vesicles [7-9] and the fusion activity of the Env
glycoprotein [10,11].
SIV and HIV Env glycoproteins contain a relatively long
cytoplasmic domain (150–200 amino acids) compared
with most other retroviral Env glycoproteins. Nonhuman
primates in Africa that are natural hosts for SIV appear to
be disease resistant when infected with SIV, whereas non-
natural Asian macaque hosts such as rhesus macaques
exhibit progressive CD4+-T-cell depletion and AIDS [12-
14]. When SIV strains were passaged on human cell lines
they frequently acquired a premature stop codon and
expressed a truncated Env glycoprotein that lacks all but
approximately 20 amino acids of the cytoplasmic domain
[15-18]. However, molecular clones of SIV with truncated
Env only establish transient infection in rhesus macaques
[19]. Variants with truncated Env are commonly isolated
from both types of infected monkeys [15,17,19]. How-
ever, variants of HIV with truncated Env are rarely isolated
from infected patients, even though HIV-1 infected
patients can harbor viruses with truncated Env that are
able to mediate CD4-independent infection of CD8+ cells
[20].
By budding through lipid rafts in T-cells, HIV and SIV
selectively incorporate raft marker proteins and exclude
non-raft proteins [21]. The depletion of cholesterol from
viral membranes inactivates and permeabilizes HIV and
SIV virions [22]. These results indicate a critical role of
lipid rafts in the biology of these viruses. It was reported
that HIV budding in primary macrophages occurs through
the exosome release pathway [23]. A non-pathogenic
molecular clone SIVmac1A11 closely related to
SIVmac239 but with a truncated Env, which was isolated
from an infected rhesus macaque, was able to replicate in
monkey macrophages, rhesus PBMC, and human T-cells.
However, a pathogenic clone of SIVmac239 was restricted
for replication in monkey macrophages and human T-
cells [16,17,24]. These results indicated that virus replica-
tion capacity in different cell lines does not correlate with
in vivo virulence.
In the present study we have compared molecularly
cloned SIV isolates with sequence differences in the Env
glycoprotein, acquired during adaption to human T cells,
to investigate the effects of the long cytoplasmic tail of the
Env glycoprotein on early steps of replication as well as
assembly of SIV. We further compared the replication of
these viruses in dividing and non-dividing cells.
Results
Properties of SIV variants
In the present study we compared SIVmac239 and several
SIVmac239 derivates with mutations in the Env glycopro-
tein resulting from adaptation to cell culture (Fig. 1).
SIVmac18 with a single mutation A239T in the SU subu-
nit and a full length cytoplasmic tail, SIVmac18T with a
single mutation A239T in the SU subunit and with a trun-
cated cytoplasmic tail, and SIVmac239T with a truncated
cytoplasmic tail were described previously [25].
SIVmac239 exhibits a low level of Env incorporation,
resistance to neutralization by antibodies and slow repli-
cation in human CEMx174 and rhesus monkey PBMC
(Table 1). SIVmac18T, a variant with a truncated Env iso-
lated by adaptation to human HUT78 cells, exhibits a
high level of Env incorporation, sensitivity to neutraliza-
tion and rapid replication in human HUT78, CEMx174
and rhesus monkey PBMC. SIVmac18, the corresponding
virus with a full length Env, also demonstrated a high level
of Env incorporation and sensitivity to neutralization, but
slow replication.
Table 1: Phenotypic properties of SIV.
Virus Phenotypic properties1
Env incorporation length of Env CT sensitivity to neutralization replication2
SIVmac239 low full low slow
SIVmac239T high truncated low slow
SIVmac18 high full high slow
SIVmac18T high truncated high rapid
1properties of SIV variants were determined previously (Vzorov et al., 2005)
2levels of replication were determined in HUT78, CEMx174 cells, and rhesus monkey PBMCRetrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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SIV post-entry replication in dividing vs. non-dividing cells
The entry mechanisms appear to be similar for T and M
tropic SIV viruses [26]. They utilize similar receptors and
coreceptors for membrane fusion and are able to use the
endocytic pathway [27]. The early events of SIV infection
include the attachment, entry, uncoating and transport of
the genome to the transcription site, formation of the pre-
integration complex (PIC), and import into the nucleus.
Not much is known about the composition of reverse
transcription complexes, particularly during the early
steps after internalization. After virus-cell fusion, viral
RNA and associated proteins are released into the cyto-
plasm and may interact with the cytoskeleton [28]. To
investigate the possible effect of Env glycoprotein differ-
ences on early steps of replication in dividing and non-
dividing cells we used an indicator cell line assay with
human epithelial HeLa cells expressing CCR5 and CD4.
The nuclear activation of a galactosidase indicator assay
does not require late events such as virion protein expres-
sion, virus particle assembly, or virion maturation [29].
To compare infection in dividing or non-dividing MAGI-
R5 cells, we used SIV viruses and Ebola GP pseudotyped
HIV at a similar titer determined as described in Methods,
to infect about 30 to 50 dividing cells. Non-dividing cells
were arrested in the G1-S phase of the cell cycle by using
aphidicolin, an inhibitor of eukaryotic DNA polymerase
α. [30]. After 3 days of infection the numbers of infected
cells were compared in dividing and non-dividing cells
(Fig. 2). Similar levels of blue staining nuclei were
observed in dividing and non-dividing cells in all sam-
ples, including cells infected by Ebola GP pseudotyped
HIV. The results indicate that import of proviral DNA of
SIV and HIV to the nucleus in dividing and non-dividing
cells occurs by mechanisms that are independent of the
differences in sequence of Env. As an alternative method,
we also used real-time PCR, which is a more accurate
method for comparison of early steps in replication (dur-
ing 24 h post transfection) of viruses with different repli-
cation rates. We used the same amounts of input virus
with an equal infectious index (IU/ng) ~3 IU/ng for each
virus as described in Methods. A high number of copies of
proviral DNA was determined in nuclei isolated from rhe-
sus monkey PBMC infected by SIV with full length Env,
and a significantly lower amount in nuclei infected by SIV
with truncated Env at 24 hr post infection: about 1.39 ×
106 DNA copies infected by SIVmac239 and about 1.3 ×
106 DNA copies infected by SIVmac18, or about 4 × 104
DNA copies infected by SIVmac239T and about 5.3 × 103
DNA copies infected by SIVmac18T (Fig. 3). We obtained
similar results with other tested cell lines CEMx174,
HUT78, rhesus monkey macrophages (not shown); with
increased multiplicity of infection for SIV viruses with
truncated Env we observed increased replication levels.
The ratio of infectious indices was 3 IU/ng of SIVmac239
to 9 IU/ng of SIVmac18 to 60 IU/ng of SIVmac239T to
450 IU/ng of SIVmac18T, or differences of 3 to 20 or 150
fold, respectively. We determined about 2 × 105 copy
numbers per 1 × 106 dividing or non-dividing CEMx174
cells for all viruses after PCR amplification (Fig. 4). The
amount of proviral DNA in nuclei isolated from dividing
and non-dividing cells infected by SIV with full length or
truncated Env was quite similar, within one PCR cycle.
The results may also indicate the possible difference
between DNA metabolism of SIV with full length or trun-
cated Env by significantly higher ratio of infectious parti-
cles to proviral DNA copies of SIV with full length than
with truncated Env.
Taken together, the results indicate that virus entry into
cells was similar for SIV with full length or truncated Env
in dividing vs. non-dividing cells. The full length Env glyc-
oprotein exhibited a significant effect on the efficiency of
Schematic representation of envelope gene products of cloned SIV adapted or not adapted to human cells Figure 1
Schematic representation of envelope gene products of cloned SIV adapted or not adapted to human cells. 
SIVmac239 has a full length 164 amino acid cytoplasmic tail (CT) [64]. The 239T construct has a truncated CT of 18 amino 
acids. A site-specific C to T mutation present in the 239T env gene changed a CAG glutamine codon at position 734 to a TAG 
termination codon. SIVmac18T contains a single amino acid substitution A239T in the SU domain designated 18 [25]. Numbers 
represent amino acid residues. Shaded boxes represent the hydrophobic transmembrane-spanning regions.Retrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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SIV postentry replication events compared with truncated
Env, but virus with truncated Env can overcome this
restriction by high multiplicity of infection.
Production of progeny SIV in dividing and non-dividing cells
To evaluate possible differences in viral particle produc-
tion in dividing vs. non-dividing cells we compared the
release of Gag antigen (p27) in SIV infected CEMx174
cells that were untreated or treated with aphidicolin for 24
hr before and during infection. To control for possible
effects of cell viability on Gag production, a parallel MTT
assay was performed. The total production of Gag was
about 2-fold lower in non-dividing cells than in dividing
cells infected by with full length Env SIVmac239 or with
the same level in both type of cells infected by mutant
SIVmac18 with full length Env (Table 2). The total pro-
duction of Gag was about 2-fold higher in non-dividing
cells than in dividing cells infected by SIV with truncated
Env (SIVmac239T, SIVmac18T). Infection with all viruses
had similar effects on viability of dividing or non-dividing
(aphidicolin treated) cells; viability of cells treated with
aphidicolin for 3 days was about 3-fold lower compared
with cells treated for 1 day. The results indicate that release
of Gag antigen into media of non-dividing cells infected
by SIV with full length Env was restricted but there was no
such inhibition for SIV with truncated Env.
In addition we compared Gag antigen production in
monkey or human monocyte-derived macrophages
infected with SIV full length or truncated Env. As a con-
trol, monkey M-tropic SIVmac1A11, a closely related
strain to SIVmac239, with truncated Env and with other
differences in sequence, important for macrophage-tro-
pism was used [31]. Cell-free supernatants were harvested
from the cultures at 7 days post-infection and tested for
the presence of Gag p27 antigen. We observed release of
Gag antigen from monkey macrophages infected by
SIVmac1A11 but not from cells infected by SIVmac239,
SIVmac239T, SIVmac18 or SIVmac18T (Table 3). A high
level of Gag antigen was released into media of human
macrophages infected by mutant SIVmac18T with trun-
cated Env, a trace amount from cells infected by mutant
SIVmac18 with full length Env, and release was not found
in supernatant of cells infected by SIVmac239,
SIVmac239T, or SIVmac1A11. The results indicate that SIV
with truncated Env predominantly produced Gag antigen
in macrophages.
To investigate the infectivity of particles released in the
supernatant of SIV infected CEMx174 cells during 3 days
Comparison of early steps of replication of SIV with full  length or truncated Env in rhesus monkey PBMC Figure 3
Comparison of early steps of replication of SIV with 
full length or truncated Env in rhesus monkey PBMC. 
Rhesus monkey PBMC (3 × 106) were inoculated by SIV with 
full length or truncated Env with an equal infectious index 
(IU/ng) using ~3 IU/ng for each virus as described in Meth-
ods. Samples of nuclear DNA were tested for the presence 
of SIV DNA by real-time PCR in a TaqMan thermal cycler at 
24 h after infection. Nuclear DNA samples corresponding to 
equal numbers of cells infected by SIV were analyzed in tripli-
cate. Fluorescence was recorded as a function of PCR ampli-
fication cycle. Quantitative SIV determinations were made by 
comparison with a standard curve produced by using serial 
dilution of plasmid DNA.
Infectivity of SIV with full length or truncated Env and pseu- dotyped HIV virions in dividing and non-dividing cells Figure 2
Infectivity of SIV with full length or truncated Env 
and pseudotyped HIV virions in dividing and non-
dividing cells. MAGI-R5 cells treated or untreated with 
aphidicolin were infected with SIVs or pseudotyped HIV viri-
ons. For inoculation of cells, each virus was used at a similar 
titer determined as described in Methods. Infectivity of SIV 
and HIV was measured by removal of the media after three 
days, fixation and staining of cells with X-gal [29]. The infec-
tivity was determined by counting the number of infected 
cells in wells inoculated with viruses. Data are plotted as the 
mean of three experiments, each replicated twice. Error bars 
represent standard deviations.Retrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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of infection from the experiment described above (Table
2), we performed a replication assay in HeLa cells express-
ing high levels of CCR5 and CD4 (JC-53B cells). The high-
est number of infectious particles was produced after 3
days post infection in all SIV infected dividing cells. We
observed infectious particles in the supernatant of
SIVmac239 infected dividing cells only after 3 days desig-
nated (100%), and no infectious particles (0%) in the
supernatant of SIVmac239 infected non-dividing cells
after 1 or 3 days. The absence of infectious particles was
also observed with the SIVmac18 mutant that carried a
full length Env. In contrast, viruses with truncated Env
(SIVmac239T, SIVmac18T) produced infectious particles
starting at early times post infection, 1 or 3 days post
infection in dividing as well as non-dividing cells (not
shown). We observed levels of about 60% infectious par-
ticles in the supernatant of SIVmac239T and about 75% in
the supernatant of SIVmac18T infected non-dividing cells
after 3 days (Fig. 5). The results demonstrate that only SIV
with truncated Env produced infectious particles in non-
dividing CEMx174 cells, although SIV with a full length
Env was able to produce and release non-infectious Gag
particles in these cells.
We also compared production of infectious particles con-
taining SIVmac239, SIVmac239T, and SIVmac18T Env in
293T epithelial cells. The virus stocks were prepared by
transfection of 293T cells with similar amounts of DNA.
The level of extracellular Gag in cells infected by
SIVmac239 was about 3-fold higher than in cells infected
by SIV239T or SIVmac18, and about 5-fold higher than in
cells infected by SIVmac18T (Table 4). The infectivity titer
in supernatants from transfected cells was analyzed using
indicator cell lines. We found that the infectivity titer of
SIV with truncated Env was about 6 to 30-fold higher than
SIV with full length Env. SIV with a full length Env appar-
ently produces reduced levels of infectious particles in
human 293T cells, although total particle release was
higher than in cells infected by SIV with truncated Env.
Taken together, the results indicated that production of
particles by SIV with full length Env was cell type depend-
ent: particles were produced in monkey PBMC and release
of particles was inhibited in human T cells and macro-
phages. In contrast, SIV with truncated Env produced
infectious particles in all types of cells tested.
Effects of modifications in the long cytoplasmic tail on 
lipid raft association and assembly of SIV in 293T cells
The SIV Env glycoprotein with a long but not with a trun-
cated CT is palmitoylated at a single cysteine at residue
position 787, which may be important for its interactions
with cellular proteins. However, mutations that change
Analysis of efficiency of SIV replication in dividing vs non- dividing CEMx174 cells Figure 4
Analysis of efficiency of SIV replication in dividing vs 
non-dividing CEMx174 cells. CEMx174 cells (2 × 106) 
treated or untreated with aphidicolin were inoculated by SIV 
with full length or truncated Env with similar titer; the 
amounts of input virus was determined based on the infec-
tious index (IU/ng) as described in Methods. At 24 h after 
infection samples of nuclear DNA were tested for the pres-
ence of SIV DNA by real-time PCR in a TaqMan thermal 
cycler. Nuclear DNA samples corresponding to equal num-
bers of cells infected by SIV were analyzed in parallel. Fluo-
rescence was recorded as a function of PCR amplification 
cycle. Quantitative SIV determinations were made by com-
parison with a standard curve produced by using serial dilu-
tion of plasmid DNA. The ratios of replication levels in 
dividing:non-dividing cells are shown.
Table 2: Production of Gag antigen SIV in dividing and non-dividing CEMx174 cells.
Virus MTT1 +aphid1day/+aphid 3 days (OD) Viability index (fold difference) p27 ng/ml2 -aphid.3 days p27 ng/ml2 +aphid.3 days (x3)3
SIVmac239 0.327/0.106 3 28 17
SIVmac239T 0.302/0.105 2.9 32 41
SIVmac18 0.334/0.104 3.2 10 12
SIVmac18T 0.386/0.117 3.7 19 41
1MTT assay is described in Methods
2Amount of Gag p27 antigen in supernatants determined by ELISA described in Methods
3amount was adjusted in according to results of MTT assay.Retrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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the full length Env glycoprotein palmitoylation state did
not alter its transport, surface expression or cell fusion
activity [32]. Since palmitoylation could be involved in
lipid raft association, the association of the Env glycopro-
tein with detergent resistant microdomains was compared
for SIVmac239 with a long cytoplasmic tail (SIVmac239-
Env), the Env mutant with a truncated TM glycoprotein
(SIVmac239-EnvT) and a palmitoylation site mutant in
which the cysteine at position 787 was changed to serine
(SIVmac239-EnvC787S). These glycoproteins were found
to be expressed and efficiently processed in human
CEMx174 cells at similar levels (not shown). However,
differences were observed in targeting of these viral enve-
lope glycoproteins to detergent-resistant membrane
microdomains (Fig. 6). The full-length wild-type as well
as the palmitoylation-deficient mutant SIVmac239Env
C787S glycoproteins were both found in the low-density
sucrose gradient fraction, while the Env glycoprotein with
a truncated cytoplasmic tail was not apparently targeted to
lipid rafts, since it was not found in the low-density frac-
tions. These results indicate that the long cytoplasmic tail
of the Env glycoprotein but not its palmitoylation is
required for incorporation of Env into lipid rafts. The SIV
viruses with truncated Env glycoproteins are therefore
able to replicate efficiently in cell lines despite their lack
of Env lipid raft association.
To compare the assembly of different Env glycoproteins
into virions, we transfected human 293T cells with equal
amounts of proviral DNA. At 3 days post transfection cells
and supernatants were collected and analyzed by RT assay
(not shown). We found similar levels of RT activity in
supernatants from cells infected by SIV with full length or
truncated Env glycoproteins. The lowest RT activity, about
100-fold lower than in other SIV samples, was observed in
supernatants from cells infected by SIV with the C787S
Env mutant which eliminated palmitoylation. The infec-
tivity titer of SIV with truncated Env was about 6 to 30-
fold higher than SIV with full length Env as described
above (Table 4). These results indicate that palmitoylation
enhances virus replication and/or assembly viruses with
full length Env but is not required in viruses with trun-
cated Env.
Effects of full length and truncated Env on host-cell gene 
expression
We also analysed the effect of Env glycoprotein differences
on cellular transcriptional responses to infection. PBMC
cells were infected with SIVmac239 variants with full
length or truncated Env glycoproteins. Both viruses
infected about 30% of cells at 6 days post infection as
detected by flow cytometry. We examined mRNAs from
Production of SIV infectious particles in dividing and non- dividing CEMx174 cells Figure 5
Production of SIV infectious particles in dividing and 
non-dividing CEMx174 cells. CEMx174 cells in a 96-well 
plate about 3 × 104 per well treated or untreated with aphidi-
colin were infected by SIV variants with the same titer deter-
mined as described in Methods. The supernatants were 
collected after 1 and 3 days post infection and the p27 con-
tent was determined by ELISA Core Antigen assay (Table 2). 
SIV particles with about 0.5 ng/well of p27 antigen were used 
for inoculation of JC-53B cells. The infectivity of particles was 
measured by removal of the media after 3 days, fixation and 
staining of cells with X-gal. The percent of particle infectivity 
was determined by dividing the number of infected cells in 
wells inoculated with particles collected from supernatants of 
SIV infected non-dividing cells by the number in wells inocu-
lated with particles collected from supernatants of SIV 
infected dividing cells after 3 days (the maximum amount for 
each virus). Data are plotted as the mean of three experi-
ments, each replicated twice.
Table 3: Production of Gag antigen SIV in macrophages.
Virus Macaque macrophages p27 ng/ml1 Human macrophages p27 ng/ml1
SIV239 0 0
SIV239T 0 0
SIV18 0 2
SIV18T 0 40
SIV1A11 15 0
1Amount of Gag p27 antigen in supernatants (24-well plate) determined by ELISA described in Methods.Retrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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SIVmac239 and SIVmac239T infected cells, and compared
transcriptional responses to those observed in uninfected
PBMC. The results were verified by real-time PCR with the
same RNA samples (Table 5). The real-time PCR data con-
firmed that SIV with full or truncated Env induced similar
cellular transcriptional responses. No changes were
observed in levels of mRNA induction by SIV with full and
truncated Env. These results show that the differences in
the Env cytoplasmic tail did not result in major differences
in effects on host-cell transcriptional responses.
Discussion
The differences in properties between SIV with full length
or truncated Env have been previously studied with
respect to pathogenicity [17], fusion activity [10,11], and
assembly [4,9,25]. In the present study we had several
goals: to study the possible role of the long cytoplasmic
tail of the Env glycoprotein in post-entry events, to exam-
ine the lipid raft association of Env glycoproteins with full
length or truncated cytoplasmic tails, and to compare
assembly and release of SIV with full length and truncated
Env in dividing and non-dividing cells. We also compared
several cloned SIV viruses with sequence differences in the
SU and CT subunits of the Env glycoprotein, that were
related to adaptation to HUT78 cells [25].
The early steps of HIV and SIV infection include the
attachment of viruses to host cells, entry and transport of
the genome to the transcription site, formation of the PIC,
and import to the nucleus. Electron microscopic studies
showed that HIV cores were disrupted shortly after virus-
cell fusion [33] and viral RNA and associated proteins
were released into the cytoplasm and were likely to inter-
act with the cytoskeleton [28]. We found that early steps
in replication of SIV with full length or truncated Env were
similar in dividing and non-dividing cells. Our results also
indicated that internalization of SIV was correlated with
amount of p24 input, but not with differences in Env glyc-
oproteins (not shown). Previous studies also indicated
that viruses might be internalized into cells irrespectively
of CD4 surface expression and with almost equal efficien-
cies in cells susceptible or not susceptible to HIV infection
[34]. The most striking differences were observed when
we compared post-entry relocation of SIV with full length
or truncated Env using similar input virus levels. The pro-
viral DNA of SIVmac239 with full length Env was trans-
ported to the nucleus about 20-fold more efficiently than
SIVmac239T with truncated Env, and 100-fold more effi-
ciently than the SIVmac18T variant with a truncated cyto-
plasmic tail and with a single mutation A239T in the SU
subunit. In contrast, the proviral DNA of SIVmac18 with
a full length Env and with a single mutation A239T in the
SU subunit was transported to nucleus almost as effi-
ciently as the parental SIVmac239. Env glycoproteins are
not involved in nuclear import of the HIV pre-integration
complex [35], which may suggest that the effects of Env
glycoproteins during early steps of SIV infection is associ-
ated with other steps in post-entry replication.
We observed release of infectious SIV particles with full
length Env in monkey PBMC cells, but a restriction of par-
ticle release in human CEMx174, HUT78, epithelial 293T,
or in macrophages. These results are consistent with pre-
vious studies indicating that replication of T-tropic SIV
Lipid raft association of the SIV Env protein Figure 6
Lipid raft association of the SIV Env protein. The inter-
action of the Env protein of SIVmac239 (A), SIVmac239-EnvT 
(B), and SIVmac239-EnvC787S (C) with lipid rafts was ana-
lyzed in a discontinuous sucrose gradient. CEMx174 (A, B, C) 
cells were infected with 2 pfu/cell of respective vaccinia 
recombinant viruses. The infected cells were labeled with 
35S-methionine/cysteine, disrupted by detergent TX-100 and 
a discontinuous sucrose gradient of 5 to 30% sucrose was 
used to obtain 11 fractions as described in Methods.
Table 4: Replication of SIV variants generated in human 293T cells.
Virusa JC-53B titerb IUc/ml ELISA (p27)b ng/ml IU/ngc (fold difference from SIVmac239)
SIVmac239 1 × 103 306 3 -
SIVmac239T 6 × 103 101 59 20
SIVmac18 1 × 103 117 9 3
SIVmac18T 3 × 104 65 461 154
aViruses were obtained simultaneously after transfection of 293T cells with equimolar amounts of DNA.
bAssays are described in Methods.
cInfectious unitsRetrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
Page 8 of 14
(page number not for citation purposes)
and HIV with full length Env is inhibited at a post-nuclear
step in macrophages [36,37]. Our results also demon-
strated that a mutation in the long cytoplasmic tail that
eliminates palmitoylation did not abolish Env incorpora-
tion into lipid rafts as was described for HIV-1 [38], but
prevented virus assembly. In contrast to HIV-1 [39] our
results indicate that palmitoylation of the SIV Env cyto-
plasmic tail is not a prerequisite association with deter-
gent insoluble microdomains. Similar results have been
reported for EBV; the interaction of LMP-1 with lipid rafts
was shown to be independent of palmitoylation [40]. Fur-
thermore, palmitoylation of viral transmembrane pro-
teins does not necessarily trigger interaction with lipid
rafts, since palmitoylated VSV G protein is found in a TX-
100 soluble membrane fraction [41]. Palmitoylation was
critical for infectivity of SIV with full length Env, and also
may impact HIV-1 infectivity [39,42]. Inhibitory factors
such as TRIM5α target the CA and/p2 components of the
incoming virus and presumably would be able to restrict
infection of both viruses with full length and truncated
Env [43,44].
In contrast to SIV with full length Env, similar levels of
assembly and release were observed for SIV with truncated
Env in monkey PBMC, human HUT78, CEMx174, 293T,
growth-arrested CEMx174 cells and macrophages result-
ing in production of infectious particles. We previously
observed that SIVmac239T Env with a truncated cytoplas-
mic tail exhibited the ability to self-associate on the cell
surface and assemble into a more closely packed array
than full-length Env [9]. Our results indicated that the
long cytoplasmic tail of the Env glycoprotein is required
for incorporation of Env into lipid rafts, but Env trunca-
tion allows SIV to replicate under conditions that are non-
permissive for SIV with the full length Env glycoprotein.
Since SIV viruses with truncated Env glycoproteins are
able to establish productive infection, lipid raft associa-
tion is apparently not required for virus replication and
truncated Env is assembled into infectious SIV virions
even though it was not incorporated into lipid rafts. Trun-
cation of the cytoplasmic domain of the SIV Env glycopro-
tein alters the conformation of the external domain and
results in more stable oligomers of TM glycoprotein [45],
and the truncated Env glycoprotein is more fusogenic
than the full length Env [10,11]. These features for incom-
ing virus particles may result in less dependence on the
lipid composition of the viral membrane. However, a
recent study reported that cholesterol-depleted HIV-1 vir-
ions exhibited a defect in internalization [46]. Taken
together, the results suggest that SIV with a truncated cyto-
plasmic tail can overcome a restriction in post-nuclear
replication events, but exhibits a defect in early replication
events in human and monkey cells.
Circulation of SIV with truncated Env among disease
resistant primates in Africa or disease sensitive primates in
Asia may indicate that this form of virus appeared when
virus is adapting to new cells such as such as epithelial on
brain cells, macrophages [47] or in response to factors
controlling pathogenicity of virus [43]. However, experi-
mental infection of monkeys by SIV with truncated Env
showed a restricted circulation of this virus in PBMC
[15,48]. Our results suggest that the restricted circulation
of Env-truncated variants in vivo may be related to a defect
in a post-entry step (Fig. 7A). The virus with full length
Env has higher specific infectivity than virus with trun-
cated Env, and is capable to establish productive infection
in permissive T cells and persistent infection in non-per-
missive cells such as epithelial and dendritic cells or mac-
rophages [49,50] because early steps in replication appear
to be more efficient in viruses having a long cytoplasmic
tail incorporated into lipid rafts domains of incoming par-
ticles (Fig. 7A, B). However, SIV with truncated Env can
overcome this early restriction by high multiplicity of
infection (Fig. 7B). A high multiplicity of infection would
be difficult to obtain by virus with truncated Env in vivo,
because of its sensitivity to the humoral immune response
[47]. This is a possible reason why a most viruses with
truncated Env were derived from tissues of immunocom-
promised macaques, or from brain tissue, an immune-
privileged site. We suggest that the long cytoplasmic tail of
the Env glycoprotein may interact with viral (p17) [1] or
cellular proteins [32]. It was shown that the HIV-1 enve-
lope glycoprotein with a long cytoplasmic tail directly
influences the site of release of Gag particles in polarized
epithelial cells [5] and microtubules may play an impor-
tant role in assembly and maintenance of the polarized
viral budding platform. Treatment of infected T cells with
inhibitors of actin or tubulin remodeling disrupted Gag
and Env compartmentalization within the polarized raft-
like domains [51]. Co-localization of the reverse tran-
scription complex with actin microfilaments and viral
matrix was also observed during early steps in replication
[28,52]. We suggest that the long cytoplasmic tail of the
Env glycoprotein may affect interaction of viral core pro-
teins with the cytoskeleton, which is important for viral
relocation to the transcriptional site. Finally, our results
may help to develop a strategy against pathogenic forms
of HIV which could prevent the initial infection process.
One example is development of topical microbicides tar-
geted to post entry inhibition of HIV infection by interfer-
ing with Env function in an early step of virus replication
[53].
Conclusion
The present results indicate that a possible basis for defec-
tive replication of SIV with truncated Env in primates may
be a restriction during an early step of replication, whereas
defective replication of SIV with full length Env in humanRetrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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T cells may result from a restriction during a late step of
replication and assembly. Comparable host-cell transcrip-
tional responses in rhesus monkey PBMC to both types of
virus infection also indicates that cells respond similarly
to replication of SIV with full length or truncated Env. A
mutation in the Env sequence relating to T cell adaptation
alters SIV properties including sensitivity to neutraliza-
tion, level of Env incorporation, rate of replication and
association with lipid rafts during the course of adapta-
tion to human cells.
Methods
Cell and virus stocks
The recombinant monkey cell lines sMAGI and human
MAGI-R5 were obtained from the NIH AIDS Research and
Reference Reagent Program. T-cell line HUT78 and T-B
hybrid cell line CEMx174 were obtained from the Ameri-
can Type Culture Collection (Manassas, VA). The recom-
binant epithelial human cell line JC53-BL (indicator cell
line), which is a derivative of HeLa cells that expresses
high levels of CD4 and coreceptors CCR5 and CXCR4
[54], was obtained from Dr. J. Kappes (University of Ala-
bama, Birmingham). The human 239T cell line was
kindly provided by Dr. S. L. Lydy. Rhesus monkey PBMCs
were separated by centrifugation of whole blood over LSM
Lymphocyte Separation Medium (ICN Biomedicals Inc.,
Costa Mesa, CA). Cells were then stimulated with conca-
navalin A (Con A, 5 µg/ml in RPMI 1640 containing 10%
heat-inactivated fetal calf serum; interleukin-2, human
(hIL-2), 10 U/ml; 10 mM HEPES; and antibiotics) for
three days before virus infection. To prepare monkey mac-
rophages, PBMC were isolated as described above. Cells
(3 × 107 in RPMI 1640 containing 15% human AB+ serum,
1.5 ng/ml of M-CSF, and 0.08 ng/ml of GM-CSF) were
seeded into 100-mm plates or split into 24-well plate and
incubated for 4 days to allow adherence of monocytes.
After removal of nonadherent cells, cells were incubated
for another 3–4 days before infection.
SMAGI, MAGI-R5, JC53-BL, and 239T cells were main-
tained in Dulbecco's minimal essential medium (DMEM)
supplemented with 10% fetal calf serum and antibiotics.
HUT78 and CEMx174 cells were maintained in RPMI
1640 supplemented with 10% fetal calf serum and antibi-
otics, and buffered by 10 mM HEPES.
Preparation of cloned SIV stocks, standardization of virus
titers, and conditions for virus infection were done as
Schematic comparison of SIV with full length and truncated Env Figure 7
Schematic comparison of SIV with full length and truncated Env. Replication of SIV with full length Env (A) or with 
truncated Env (B) in permissive (monkey PBMC) cells (left diagrams) and non-permissive cells (brain cells, macrophages) (right 
diagrams). Schematic depiction of the trafficking of SIV in cells: Gray dashed arrows depicted raft-associated pathway; black 
dashed arrow depicts alternative pathway; black arrows depicted sites of transcription. SIV with truncated Env can overcome a 
restriction in an early replication step by high multiplicity of infection and productively infect cells.Retrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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described earlier [25]. It is commonly accepted to use the
infectious titer [55] or TCID50 [56] for measurement of
the quantity of SIV and HIV. However, these methods are
not able to precisely compare viruses with different prop-
erties such as rate of replication or production of non-
infectious particles. We used infectious the index (IU/ng)
which is the ratio between infectious titer and core anti-
gen, which is taking both of these characteristics into con-
sideration.
Prior to cell infection, virus preparations were treated with
200 U/ml RNase-free DNase I in growth medium contain-
ing 10 mM MgCl2 for 30 min 37°C to remove contami-
nating proviral DNA [57]. Plasmid pHIVSG3 containing
the HIV-1 provirus (SG3) with a deleted env gene was a
generous gift from Beatrice Hahn. Plasmid pCMV-GP
encoding the Ebola envelope protein GP was provided by
C. Yang. The plasmid pRB239ser-787 which carried a
mutation in the long cytoplasmic tail of the Env glycopro-
tein of SIVmac239 C787S to eliminate palmitylation (see
below) was digested by NheI and BglII and the resulting
fragment with the mutation was introduced in plasmid
p3'239 which contained the 3' portion of molecularly
cloned SIVmac239 [25] in identical restriction sites. The
plasmid, designated p3'239ser-787, was used to obtain a
mutant virus as described above.
Construction of recombinant vaccinia viruses
Recombinant vaccinia viruses expressing the SIVmac239-
Env or SIVmac239-EnvT were described previously [9].
For the construction of SIVmac239-EnvC787S the codon
TGC (cysteine) was changed to AGT (serine) by overlap-
ping PCR. The env gene was amplified from p239SpE3'
(NIH AIDS Research and Reference Reagent Program) by
using the following primers: primer A (with EcoRI restric-
tion site), CAAAGAATTCAGTATGGGATG; primer B
(overlapping primer), GGTTTCTACTGTTGCTGA; primer
C (overlapping primer), TCAGCAACAGTAGAACC; and
primer D (with restriction site of StuI), GTATTTCTAG-
GCCTCACAAGAG. Primers B and C carried the codon to
be changed. Two PCR amplifications were carried out by
using the p239SpE3' plasmid as template. Each PCR was
carried out for 25 cycles with steps of 1 min at 95°C, 2
min at 50°C, and 3 min 72°C. The PCR products were
purified with a gel extraction kit (Qiagen) according to the
manufacturer's protocol. The two overlapping PCR frag-
ments AB and CD were joined by mixing and a PCR reac-
tion with the external primers A and D was performed.
The resulting PCR fragment AD was initially cloned in the
pDrive vector (Qiagen). The plasmid was digested with
EcoRI and StuI and the fragment was cloned in vector
pRB21. The resulting plasmid was designated pRB239ser-
787 and used for preparation of recombinant vaccinia
virus as described [58].
SIV infection
Conditions for infection with SIV were described previ-
ously [25]. At 24 h before infection, 3 × 106 cells were
treated with 5 µg/ml aphidicolin, and cells were inocu-
lated with SIV for 2 h in medium with 15 ug/ml DEAE-
dextran with or without aphidicolin.
After this incubation unbound virus was removed by three
washes and medium with or without aphidicolin was
added. For 3 day samples, new medium with 5 µM AZT
and with or without aphidicolin was added after 1 day.
After 1 and 3 days, the culture supernatant and cells were
harvested from each well and used for assays. The p27
content was determined by ELISA Core Antigen assay
(Coulter Corporation). The infectivity of virus particles
was determined by β-galactosidase assays in JC53-BL [54],
MAGI-R5 or SMAGI cells [29,59].
Supernatants, cell and nuclear extracts
The supernatants were harvested and clarified by centrifu-
gation at 3.5 k for 20 min (GS-15R, Beckman). Cells were
washed three times with PBS and lysed in RIP buffer [9]
and production of Gag antigen was analyzed by SIV Core
Antigen Assay (Coulter Corporation). The culture super-
natants were also assayed for RT activity by colorimetric
reverse transcriptase assay (Roche).
Table 5: Comparison of mRNA responses by real-time PCR1.
Genes SIVmac239T/SIVmac239 (fold difference)2
IL2 1.34
IL4 1.76
IL6 -1.32
IL7 -1.41
IL10 -1.05
IL12p40 1.09
IL15 -1.16
IFNA1 1.13
IFNα 1.15
IFNβ 1.04
IFNγ -1.14
Mx -2.22
TNFa -1.11
IRF1 1.09
IRF2 1.05
IRF3 -1.09
IRF4 1.09
IRF5 1.13
IRF7 -1.27
PU.I 1.06
SPIB -1.05
1RNA samples were the same as used for microarray assay.
2Changes in cellular mRNA levels after infection by SIV with full length 
Env were compared with mRNA levels in cells infected by SIV with 
truncated Env and expressed in folds.
Note fold repression is indicated by a minus signRetrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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To prepare cell extracts, the cells (3 × 106) were suspended
in 0.01 M NaCl, 0.01 M MgCl2 [pH 7.4] for 10 min on ice
and then lysed by addition of NP-40 to 1% followed by
vortexing as described previously by [36]. Nuclei were
recovered by centrifugation at 12,000 × g for 2 min, and
nuclear DNA was extracted with a Dneasy Tissue kit (Qia-
gen) and analyzed by RT-PCR.
RNA preparation and microarray analysis
Total RNA was extracted from cells by using the Rneasy kit
(Qiagen, Valencia, CA), according to the manufacturer's
protocol. Reverse transcription, second-strand synthesis,
and probe generation were accomplished by standard
Affymetrix protocols. The Gene Chip HG_U133_Plus 2.0
array (Affymetrix), containing ≈ 33,000 known genes, was
hybridized, washed, and scanned according to Affymetrix
protocols within the Baylor Affymetrix Core facility.
Changes in cellular mRNA levels after SIV infection were
compared with mRNA levels in controls that were identi-
cally plated, treated, and incubated in the absence of virus.
GeneSpring, version 6.2 was used to normalize and scale
results and compare viral responses to those of controls.
The program clusters increases or decreases of expression
levels as the fold change relative to control.
Real-time PCR amplification for SIV
Quantification of proviral DNA from infected cells was
performed by real-time PCR using the TaqMan amplifica-
tion system as described elsewhere [37]. For PCR amplifi-
cation for the SIV gag region, forward and reverse PCR
primers were SIVgagF AGTACGGCTGAGTGAAGGCAGTA
and SIVgagR GACCCGCGCCTTTATAGGA, respectively.
The fluorogenic SIVgag probe CGGCAGGAACCAACCAC-
GACG was modified with FAM/TAMRA [37]. PCR ampli-
fication for the SIV 2LTR region was carried out. Forward
and reverse PCR primers were U3U5-2LTRF
GGAACGCCCACTTTCTTGATGTATA and U3U5-2LTRR
CGGCGGCTAGGAGAGATG. The fluorogenic 2LTR probe
was SIV U3U5-2LTRM2 FAM AACACACACTAGCTAATA-
CAG. Nuclear DNA samples corresponding to equal num-
bers of cells infected by SIV were analyzed in parallel.
Fluorescence was recorded as a function of PCR amplifica-
tion cycle. Quantitative SIV determinations were made by
comparison with a standard curve produced by using
serial dilution of plasmid DNA with a 1890 bp region of
the SIVmac239 gag gene [60].
RNA isolation and cDNA synthesis
To determine the mRNA transcription profile of selected
genes the relative quantitative real-time PCR was per-
formed. PBMC were harvested from cell culture and lysed
immediately with 350 µl of lysis buffer from the MagNA
Pure LC RNA Isolation Kit III (Tissue) (Roche), then fro-
zen at -80°C. Collected samples were extracted with a
MagNa Pure LC – robotic workstation (Roche Molecular
Biochemicals) with the same kit using the external lysis
protocol. Total RNA was eluted in 60 µl of water and opti-
cal density measurements were taken immediately. All
total RNA was reverse-transcribed using a High-Capacity
cDNA Archive Kit Protocol (Applied Biosystems Inc.).
Quantitative Real-Time PCR Analysis
The reaction was carried out on a 384-well optical plate
(Applied Biosystems) in a 20-µl reaction volume contain-
ing 30 ng of cDNA per reaction with TaqMan Universal
PCR Mastermix, Applied Biosystems. All sequences were
amplified using the Applied Biosystems 7900HT
Sequence Detection System with the PCR profile: 50° for
2 min, 95°C for 10 min, followed by 45 cycles at 95°C for
15 s, and 60°C for 1 min. Samples were tested in dupli-
cate, in parallel with the housekeeping gene GUSB. For
relative quantitation delta-delta Ct analysis was applied to
recalculate the fold differences between samples.
Primer and probe sequences
Oligonucleotide primers and probes for IL-2, IL-4, IL-6,
TNF-α, IFN-α, TNF-β, and Mx were used as described by
[61]. For IL-10 were used two sets of primers and probes.
For IL-10 assay a first set of oligonucleotide primers and
probe were used as described by [62] and a second set
described below. For other assays oligonucleotide primers
and probes were designed using the Primer Express Soft-
ware (Applied Biosystems) based on published rhesus
macaque sequences.
IFNγ : F – GAAAAGCTGACCAATTATTCGGTAA,
R – GCGACAGTTCAGCCATCACTT,
P – 5'FAM – CCAACGCAAAGCAGTACATGAACTCATCC
– TAMRA-3';
IL10: F – GTCATCGATTTCTTCCCTGTGAA
R – CTTGGAGCTTACTAAAGGCATTCTTC
P – 5'FAM – CCTGCTCCACGGCCTTGCTCTTG –
3'TAMRA;
IL-12p40: F – TGAAGAAAGACGTTTATGTTGTAGAATTG,
R – TGGTCCAAGGTCCAGGTGAT,
P – 6FAM – CTGGTACCCGGATGC – MGBNFQ
IL-7: F – GATGGCAAACAATATGAGAGTGTTCT,
R – CAATTTCTTTCATGCTGTCCAATAAT,
P – 6FAM – TGGTCAGCATCGATC-MGBNFQ;Retrovirology 2007, 4:94 http://www.retrovirology.com/content/4/1/94
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IL-15 F – AGCTGGCATTCATGTCTTCATTT,
R – CACCCAGTTGGCTTCTGTTTTAG,
P – 6FAM – CTGTTTCAGTGCAGGGC – MGBNFQ.
Primers and probes were obtained from Applied Biosys-
tems with assay ID as follows: SPIB – Hs00162150_m1;
PU.1 – Hs00231368_m1; IRF1 – Hs00971959_m1; IRF2
– Hs00180006_m1; IRF3 – Hs00155574_m1; IRF4 –
Hs00277069_m1; IRF5 – Hs00158114_m1; IRF7 –
Hs00185375_m1; IFNA1 – Hs00256882_s1. All these
assays were designed based on human sequences, and
before implementation all assays were validated for rhe-
sus macaques.
Isolation of lipid raft proteins
Radioactively labeled cells expressing different recom-
binant Env glycoproteins were washed three times with
ice cold PBS+++ and then lysed on ice in 750 µl TNE
buffer (10 mM Tris HCl pH 7.5, 150 mM NaCl, 5 mM
EDTA with a protease inhibitor cocktail (Roche)) with
0.5% (v/v) TX-100 for 20 min as described previously
[63]. The lysate was passed 10 times through a 25 G nee-
dle on ice and subsequently centrifuged at 8000 × g for 10
min at 4°C. The supernatant was brought to 40% sucrose
by adding 750 µl of 80% (w/v) sucrose in TNE, loaded
into the bottom of a SW41 centrifuge tube and overlaid
with 6 ml of 30% (w/v) sucrose in TNE and 3.5 ml 5% (w/
v) sucrose in TNE. The samples were spun to equilibrium
at 200,000 × g for 13–16 hr. Eleven fractions with volume
of each 1 ml were collected started from the top of the gra-
dient and subjected to immunoprecipitation with mon-
key anti-SIV serum. Samples were analyzed with an SDS-
8% PAGE gel and subsequent autoradiography.
MTT assay
For the MTT assay, aphidicolin treated or untreated
CEMx174 cells in 96-well plates were infected with SIV.
After 24 h or 72 h incubation, 10 µl of MTT (10 mg/ml)
reagent was added to 100 µl of medium in each well. After
4 h incubation at 37°C, 100 µl acidic isopropanol (0.04
M HCl in absolute isopropanol) was added. The absorb-
ance was read in a computer-controlled photometer. The
absorbance at 690 nm was automatically subtracted from
the absorbance at 540 nm to eliminate the effects of non-
specific absorption. The MTT assay, which provides an
indication of mitochondrial integrity and activity, is not
dependent on the cell cycle.
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